|Slideshows|April 10, 2018

Substance-Induced Psychosis and Conversion to Schizophrenia

Up to 50% of cases of cannabis-induced psychosis covert to schizophrenia. A new study provides striking evidence for abuse of other substances and schizophrenia onset.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Catatonia Crisis: Navigating the IV Lorazepam Shortage

ByLeah Kuntz

December 4th 2025

Delay on Cobenfy Alzheimer Disease Psychosis Data Following Phase 3 Study “Irregularities,” New Patients Enrolled

ByLeah Kuntz

December 3rd 2025

antidepressants negative symptoms schizophrenia

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

ByKenneth J. Bender, PharmD, MA

December 2nd 2025

Looking Back: Key Insights from November 2025

ByJessica Walters

November 28th 2025

Using Long-Acting Injectables to Reduce Rates of Relapse: Insights From Erin Crown, MHS, PA-C, Psych-CAQ

ByErin Crown, MHS, PA-C, Psych-CAQ

November 25th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Substance-Induced Psychosis and Conversion to Schizophrenia

Newsletter

Related Content

Catatonia Crisis: Navigating the IV Lorazepam Shortage

Delay on Cobenfy Alzheimer Disease Psychosis Data Following Phase 3 Study “Irregularities,” New Patients Enrolled

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

Looking Back: Key Insights from November 2025

Using Long-Acting Injectables to Reduce Rates of Relapse: Insights From Erin Crown, MHS, PA-C, Psych-CAQ

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State